(NewsDirect)
Amplia TherapeuticsLtd (ASX:ATX) CEO Chris Burns joins Proactive’s Jonathan Jackson todiscuss the company’s busy quarter and what investors can expectover the coming months. Burns talks us through the completion of thePhase1B stage of the ACCENT clinical trial in advanced pancreaticcancer patients and the promising early signs of drug efficacy thathave resulted. The company has now started its Phase2a trial, dosingpatients in January. Further to this, there’s also been good newsfrom Korea. Korean drug regulators have approved the company’sapplication to conduct the ACCENT trial in that country and Koreansites are ready to recruit patients. Finally, Burns discusses anInvestigational New Drug application (INDA) submitted to the FDA andwhat that means for the company moving forward.
Burns said:“Clearance of the IND by the US FDA is a significant step forwardfor the company. We will now start planning the combination trial ofnarmafotinib with FOLFIRINOX in the US, which expands the clinicalopportunities for our best-in-class FAK inhibitor.
"FOLFIRINOX is thepreferred treatment for pancreatic patients in the USA and most ofEurope, and therefore this combination trial is highly relevant as weposition narmafotinib as the preferred drug to enhance theeffectiveness of existing chemotherapy combinations in pancreaticcancer.”
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.